RT期刊文章SR电子T1耐药结核病治疗中的不良事件监测:VO 54 IS 6 A1 Borisov, Sergey A1 Danila, Edvardas A1 Maryandyshev, Andr188bet官网地址ei A1 Dalcolmo, Margareth A1 Miliauskas, Skaidrius A1 Kuksa, Liga A1 Manga, Selene A1 Skrahina, Alena A1 Diktanas, Saulius A1 Codecasa, Luigi Ruffo A1 Aleksa, Alena A1 Bruchfeld, Judith A1 Koleva, Antoniya A1 Piubello, Alberto A1 Udwadia, Zarir Farokh A1 Akkerman，Onno W. A1 Belilovski, Evgeny A1 Bernal, Enrique A1 Boeree, Martin J. A1 Cadiñanos Loidi, Julen A1 Cai, Qingshan A1 Cebrian Gallardo, Jose Joaquín A1 Dara, Masoud A1 davidaviien, Edita A1 Forsman, Lina Davies A1 De Los Rios, Jorge A1 Denholm, Justin A1 drakien, Jacinta A1 Duarte, Raquel A1 Eltaeb, Seifeldin Eltaeb A1 Escobar Salinas, Nadia A1 Ferrarese, Maurizio A1 Filippov, Alexey A1 Garcia, Ana A1 García-García, José-María A1 Gaudiesiute, Ieva A1 Gavazova, Blagovesta A1 Gayoso，Regina A1 Gomez Rosso, Roscio A1 Gruslys, Vygantas A1 Gualano, Gina A1 Hoefsloot, Wouter A1 Jonsson, Jerker A1 Khimova, Elena A1 Kunst, Heinke A1 Laniado-Laborín, Rafael A1 Li, Yang A1 Magis-Escurra, Cecile A1 Manfrin, Vinicio A1 Marchese, Valentina A1 Martínez Robles, Elena A1 Matteelli, Alberto A1 maza - stalder, Jesica A1 Moschos, Charalampos A1 Muñoz-Torrico, Marcela A1 Mustafa Hamdan, Hamdan A1 nakerien, biruta1 Nicod, Laurent A1 Nieto Marcos, Magnolia A1 Palmero，多明戈·胡安A1帕尔米耶里，法布里齐奥A1帕帕瓦西莱乌，阿波斯托洛斯A1帕耶恩，玛丽-克里斯汀A1庞塔雷利，阿戈斯蒂娜A1 Quirós，萨莱A1伦登，阿德里安A1萨达里，劳拉A1 Šmite，阿格内塞A1索洛维奇，伊万A1苏莱曼尼，马哈马杜·巴西鲁A1塔多里尼，玛丽娜A1范登布姆，马丁A1维斯科沃，玛丽莎A1维吉尔阿尼，彼得罗A1耶迪尔巴耶夫，阿斯卡尔A1扎布洛克里斯，罗兰达斯A1朱尔金，德米特里A1齐格诺，马泰奥A1维斯卡，蒂娜A1斯潘内洛，安东尼奥A1卡米内罗，José A. A1阿尔芬纳，简-威廉A1提贝里，Simon A1 Centis, Rosella A1 D'Ambrosio, Lia A1 Pontali, Emanuele A1 Sotgiu, Giovanni A1 Migliori, Giovanni Battista YR 2019 UL //www.qdcxjkg.com/content/54/6/1901522.abstract AB世界卫生组织(世卫组织)建议各国实施药物警戒并收集有关主动药物安全监测(aDSM)和不良事件管理的信息。本前瞻性研究的目的是评估连续使用新(如贝达奎林、地拉曼尼)和改用(如氯法齐明、利奈唑胺)药物治疗的结核病患者队列中抗结核(TB)药物不良事件的频率和严重程度，以世卫组织aDSM项目为基础。在诊断和治疗期间，将不良事件归因到特定药物后，连同人口学、细菌学、放射学和临床信息一起前瞻性收集。这项中期分析包括在数据收集时已完成或仍在接受治疗的患者。在全球范围内，来自26个国家/地区的45个中心报告了658名患者(68.7%为男性，4.4%艾滋病毒合并感染)接受如下治疗:87.7%使用贝达奎林，18.4%使用德拉曼尼(6.1%同时使用)，81.5%使用利奈唑胺，32.4%使用氯法齐明。总体而言，共报告了504起不良事件:447例(88.7%)为轻微(1-2级)，57例(11.3%)为严重(3-5级)。 The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone.The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.Previous evidence on adverse events is available from single studies. This global project (658 patients from 26 countries) demonstrates aDSM is feasible and serious adverse events of recommended drugs are reasonably low (overall 57 out of 504, 11.3%). http://bit.ly/2kzvbqe